Literature DB >> 14570366

Interval jejunoileal bypass reduces the morbidity and mortality of Roux-en-Y gastric bypass in the super-obese.

James R Arteaga1, Sergio Huerta, Nicole R Basa, Edward H Livingston.   

Abstract

Among Roux-en-Y gastric bypass (RYGB) patients, large male patients carry the greatest risk for severe, life-threatening complications. The higher complication rate is partly related to large amounts of intra-abdominal fat that increases the technical difficulty of the RYGB. In order to minimize the risk for complications, we established a staged approach for weight loss surgery for high-risk, super-obese patients. Patients with intra-abdominal fat at exploration which precluded the performance of RYGB underwent jejunoileal bypass (JIB). Following an initial period of weight loss (6-24 months), they were converted to a RYGB during a second operation. Twenty-four patients underwent initial JIB that was associated with a major complication rate of 8.3 per cent (2/24) and no mortality. Eight patients lost 53.4 +/- 6.3 kg prior to their conversion to RYGB (mean, 14.1 months). There was one major complication (12%) and no deaths (0%). Following RYGB, an additional period of weight loss resulted in overall excess weight loss (EWL) totaling 62 per cent. A two-step procedure is a safe and effective approach for minimizing complications for high-risk patients undergoing RYGB. The initial JIB was associated with low morbidity and no mortality, and the follow-up RYGB procedure was a technically simple operation that could be performed with few complications.

Entities:  

Mesh:

Year:  2003        PMID: 14570366

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  1 in total

1.  Preoperative weight loss decreases the operative time of gastric bypass at a Veterans Administration hospital.

Authors:  Sergio Huerta; Serag Dredar; Elizabeth Hayden; Ali A Siddiqui; Thomas Anthony; Massimo Asolati; J Esteban Varela; Edward H Livingston
Journal:  Obes Surg       Date:  2008-05       Impact factor: 4.129

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.